İşyeri, işyerine bağlı yerler, eklentiler ve araçlarla birlikte bir bütün kabul edilmektedir. Bir fiziki birimin işyerine bağlı yer niteliğini haiz olmasının toplu iş ilişkileri üzerinde önemli etkileri vardır. Türk toplu iş hukukunda sendikalar işkolu düzeyinde kurulur ve işkolu da kural olarak her işyeri özelinde tespit edilir. Bu bakımdan bir fiziki birimin bağlı yer sayılması veya sayılmaması öncelikle ilgili yerde sendikal örgütlenmenin gerçekleşeceği işkolunu etkileyebilmektedir. Öte yandan Türk toplu iş hukukunda işyeri, işletme ve grup toplu iş sözleşmesi olmak üzere üç tür toplu iş sözleşmesi bulunmaktadır. Bir fiziki birimin bağlı yer niteliği, somut olayın özelliklerine göre işyeri veya işletme toplu iş sözleşmesinin yapılmasını gerekli kılabilir. Bu etki aynı zamanda toplu iş sözleşmesinin yapılması için gereken yetki belgesinin alınması noktasında işyeri veya işletme barajının aranmasına sebep olacaktır. Tüm bu etkiler, uygulamada tarafların bir fiziki birimin bağlı yer sayılması veya sayılmamasına sıklıkla itiraz etmesine sebep olmaktadır. Bu itirazların hangi hallerde yetki işlemleri için bekletici mesele yapılabileceği bir diğer önemli sorun olarak çalışmamızda tartışılmıştır. Son olarak çalışmada Sosyal Güvenlik Kurumu kayıtlarının işkolu tespitine etkilerine değinilmiş ve uyuşmazlıkların önlenmesi adına öneriler getirilmiştir.

Frailty in oncology is a major determinant of treatment toxicity and survival, and is often framed primarily as a muscle problem. Adipose tissue, however, is an active endocrine and metabolic organ, and its glycolytic activity on positron emission tomography/computed tomography with fluorodeoxyglucose (18 F-FDG PET/CT) may capture physiological vulnerability that is not reflected by body composition alone. We investigated the association between adipose glycolytic activity and frailty in older adults with solid tumours. We prospectively enrolled 104 adults (≥ 50 years) with solid malignancies (median age 63.5 years) who underwent clinical whole-body 18 F-FDG PET/CT and a comprehensive geriatric assessment on the same day. At the L3 level, adipose area and metabolic activity (SUVmean and rSUVmax; SUVp95-derived and reference-normalized hereafter referred as SUVmax for simplicity) were quantified using a deep learning segmentation pipeline (TotalSegmentator) with strict exclusion of visceral structures to isolate adipose signal. Frailty was assessed using the Clinical Frailty Scale (CFS) and the FRAIL Scale. Total adipose area did not differ between frail and non-frail phenotypes (425.64 vs. 424.38 cm², p = 0.45). In contrast, adipose glycolytic activity was significantly higher in frail patients (SUVmean 0.30 vs. 0.20, p < 0.001). In multivariable logistic regression adjusted for age and sex, each 0.1-unit increase in adipose SUVmean was associated with 1.78-fold higher odds of frailty (95

To compare the diagnostic performance of 18 F-Fluorodeoxyglucose (FDG) and 68Ga-fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) in gastrointestinal malignancies, with particular emphasis on lesion detection, peritoneal disease assessment, and the potential added value of dual-time-point FAPI imaging. Thirty-eight patients with histologically confirmed gastrointestinal cancers who underwent both FDG and FAPI PET/CT within a 4-week interval were retrospectively analyzed. FAPI PET/CT images were acquired at 10 and 60 min after tracer injection. Patient-level analyses (staging/restaging accuracy, impact on management) and lesion-based analyses (detection rate, characterization, maximum standardized uptake value [SUVmax] dynamics, lesion size) were evaluated against follow-up data as the reference standard. FAPI PET/CT demonstrated superior agreement with the reference standard compared with FDG PET/CT for staging and restaging (κ = 0.91 vs. 0.32). On lesion-based analysis, FAPI showed markedly higher detection rate for malignant lesions (86

This study aimed to evaluate the utility of Total Lesion Somatostatin Receptor expression (TLS), a volumetric imaging biomarker integrating tumour burden and tumour somatostatin receptor density, for early response assessment and progression-free survival (PFS) prediction in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT). We retrospectively evaluated the baseline and post-therapy [68Ga] Ga-DOTATATE PET/CT scans of 49 patients. TLS was calculated for every target lesion. The therapeutic response defined by TLS was compared with RECIST 1.1 and PERCIST criteria. The prognostic significance of baseline parameters, including Ki-67 index, hemograms, liver and renal function tests and metabolic parameters derived from imaging was analysed using Cox regression. At a median follow-up of 32.6 months, TLS-based response assessment demonstrated superior PFS stratification compared to RECIST 1.1 and PERCIST. Notably, TLS reclassified 76

PSMA PET/CT is commonly used for selecting candidates for [& sup1;Lu-7(7)]-PSMA radioligand therapy (LuPSMA RLT). However, discrepancies may occur due to pharmacokinetic and biodistribution differences between [Ga-6(8)]-PSMA-11 and [& sup1;Lu-7(7)]-PSMA-617 ligands. Such discordance risks underestimating disease burden and excluding eligible patients. We present a case of metastatic castration-resistant prostate cancer (mCRPC) in whom a PSMA-negative adrenal lesion on PET exhibited significant LuPSMA uptake post-therapy and was subsequently confirmed as FDG-avid. Complementary stereotactic body radiotherapy (SBRT) achieved metabolic remission. This case highlights the clinical significance of integrating post-therapy LuPSMA imaging and FDG PET/CT with systemic treatment to ensure accurate disease characterization and personalized management of PSMA-/FDG+ lesions in advanced prostate cancer.

Pulmonary subsolid nodules (SSNs) represent a heterogeneous spectrum, ranging from common benign conditions to malignancies with variable growth patterns. Standardized management criteria for SSNs remain unclear, and therapeutic decisions often need to be individualized. This study aims to identify indicators for invasiveness that may guide optimal treatment decisions. This retrospective study analyzed 92 SSNs from 86 patients who underwent surgery between 2012 and 2022. Clinical data were obtained from the hospital database, and computed tomography (CT) scans, positron emission tomography (PET)/CT images, and histopathological sections were independently re-evaluated regardless of the original reports. The mean age was 61 ± 10 years; 53.5

To compare the acute (within 30 days of treatment) laboratory toxicities of Yttrium-90 (Y-90) resin and glass microspheres. Selective intra-arterial radionuclide therapies (SIRTs) with Y-90 resin and glass microspheres were retrospectively reviewed. Liver-hematological data were collected at baseline and at 1 week and 1 month follow-up. The percentage change of laboratory data and the albumin–bilirubin (ALBI) score were calculated. A total of 219 SIRTs (n: 110 resin, n: 109 glass) from 177 patients were included. There was no difference in age, liver pathologies, extrahepatic disease, baseline liver function tests, and total blood counts between the two microsphere groups. Administered activity was higher in treatments with Y-90 glass microspheres (p < 0.001). An increase in serum liver enzymes was observed after treatment with both microspheres. The difference between the treatment groups was the higher percentage increase of AST and ALT at the first week following Y-90 glass treatment (p < 0.001). However, this situation was not observed after 1 month. No difference in the percentage change of other laboratory parameters was found between two groups. The number of patients with an increase [resin n: 24 (24.7

Pathophysiological backgrounds of idiopathic Parkinson’s disease (IPD) and autosomal recessive monogenic Parkinson’s disease (AR-PD) have common features that can be assessed through multimodal imaging. In this study, the striatal and myocardial dopaminergic innervation, brain 18F-FDG metabolism, resting-state functional activity of basal ganglia network (BGN) and white-matter (WM) microstructure were evaluated in AR-PD with respect to IPD, to investigate whether AR-PD can be subtyped as “brain-first” parkinsonism according to recent etiopathogenetic classification effort. Forty patients (17 with Parkin, 3 with DJ-1 mutations and 20 with IPD) were included. Striatal dopaminergic innervation was assessed semi-quantitatively by 18F-DOPA PET, and cardiac 18F-DOPA uptake was also evaluated. Brain 18F-FDG PET images were evaluated visually. Resting-state functional MRI and diffusion tensor imaging (DTI) were used to assess the BGN activity and WM microstructural alterations. AR-PD patients showed significantly decreased 18F-DOPA uptake in caudate corpus compared to both IPD and controls, with a more symmetrical striatal dopaminergic denervation. Myocardial 18F-DOPA uptake in AR-PD was similar to controls, while it was significantly reduced in IPD. There was no significant difference in cortical 18F-FDG metabolism and functional activity of BGN between PD groups. The DTI data revealed more extensive WM microstructural damage in AR-PD compared to IPD. AR-PD group showed additional significant decreased 18F-DOPA uptake in caudate corpus and more symmetrical striatal denervation. Additionally, relatively preserved myocardial innervation, cortical metabolic and WM microstructural changes suggest the possibility of “brain-first” type progression in AR-PD. Also, 18F-DOPA PET/CT may be a practical tool for evaluating dopaminergic innervation of striatum and heart together, but further evaluation is needed in this area.

PSMA PET/CT is commonly used for selecting candidates for [¹⁷⁷Lu]-PSMA radioligand therapy (LuPSMA RLT). However, discrepancies may occur due to pharmacokinetic and biodistribution differences between [⁶⁸Ga]-PSMA-11 and [¹⁷⁷Lu]-PSMA-617 ligands. Such discordance risks underestimating disease burden and excluding eligible patients. We present a case of metastatic castration-resistant prostate cancer (mCRPC) in whom a PSMA-negative adrenal lesion on PET exhibited significant LuPSMA uptake post-therapy and was subsequently confirmed as FDG-avid. Complementary stereotactic body radiotherapy (SBRT) achieved metabolic remission. This case highlights the clinical significance of integrating post-therapy LuPSMA imaging and FDG PET/CT with systemic treatment to ensure accurate disease characterization and personalized management of PSMA-/FDG+ lesions in advanced prostate cancer.